Scope, Claims, and Patent Landscape for US Drug Patent 12,042,474
US Patent 12,042,474 covers an oral once-daily lacosamide dosage form that combines an immediate-release (IR) portion and an extended-release (ER) portion designed to match specific exposure (AUC) targets relative to a reference IR regimen given twice daily. The core claim structure is exposure-driven: it ties a defined ER/IR drug ratio and dissolution behavior to quantitative pharmacokinetic windows across multiple post-dose intervals.
What is the invention protected by US 12,042,474?
The patent’s protected subject matter is a fixed dosage-form architecture and release/exposure performance for lacosamide (or its pharmaceutically acceptable salt) where:
- The dosage form is administered orally once per day.
- The formulation has:
- An ER portion containing a first portion of lacosamide.
- An IR portion containing a second portion of lacosamide.
- The total lacosamide content in the dosage form is at least 20% by weight.
- The ER portion drug split vs IR portion drug split follows a weight ratio:
- ER first portion : IR second portion = about 15:1 to about 1:1.
- The once-daily product must meet quantitative AUC equivalence/acceptance windows relative to a matched total daily exposure from a twice-daily IR reference.
Anchor claim (Claim 1): ER/IR ratio + exposure windows
Claim 1 is the structural and pharmacokinetic “gatekeeper”:
- ER/IR weight ratio: 15:1 to 1:1
- Total lacosamide loading: ≥ 20% by weight
- Exposure targets (once-daily vs twice-daily IR reference):
- (a) AUC0-3h ≥ 40% of reference AUC0-3h
- (b) AUC0-6h ≥ 60% of reference AUC0-6h
- (c) AUC12-24h is 80% to 125% of reference AUC12-24h
Claim 2-5 refine additional AUC sub-ranges across intermediate and later time windows.
How broad are the independent and dependent claims?
Claim 1 is broad on formulation form but narrow on performance
Claim 1 does not lock the dosage into a single physical format at the independent level. It protects any oral dosage form that satisfies:
- the IR + ER functional split
- ER/IR drug ratios
- total lacosamide loading
- AUC targets
From a freedom-to-operate perspective, Claim 1 is broad in that it allows multiple architectural embodiments (layered tablet, capsule, particulates, mini-tablets), but it is narrow in that it demands specific AUC performance relative to the defined reference IR.
Claims 2-5: additional AUC windows
Claim 2 adds AUC bands:
- AUC0-6h: 80% to 125%
- AUC0-8h: 80% to 125%
- AUC0-12h: 80% to 125%
Claims 3-5 further extend later window coverage:
- Claim 3:
- AUC12-14h: 80% to 125%
- AUC12-16h: 80% to 125%
- Claim 4:
- AUC12-20h: 80% to 125%
- AUC16-20h: 80% to 125%
- Claim 5:
These are not alternative technologies. They stack additional numeric constraints on top of Claim 1’s baseline AUC0-3h, AUC0-6h minimums and AUC12-24h range.
What dosage-form architecture is covered?
Claims 6-17 define specific release-device embodiments and material/dissolution behaviors.
ER/IR placement and coating/matrix concept (Claim 6)
The IR portion can enclose the ER portion:
- IR encloses ER
- ER drug (first portion) is:
- in an ER matrix and/or
- coated with an extended release agent
Layered compressed construction (Claim 7)
Two-layer design:
- a first layer for IR and a second layer for ER
- layers are compressed together
Multi-particulate packaging options (Claims 8-10)
Multiple particulates are allowed. Two variants:
- Same particulates contain both IR and ER (Claim 8)
- Separate particulates:
- ER particulates and IR particulates
- either admixed together (Claim 9) or physically separate (Claim 10)
Independent selection of dosage-form components (Claim 11)
The ER and IR portions can each be independently selected from:
- mini-tablets, tablet, particulates, capsule, powder
Specific formats captured (Claims 12-13)
- capsule (Claim 12)
- tablet, optionally with inert core (Claim 13)
ER drug fraction tuning (Claim 14)
A further quantitative band on ER drug content:
- first portion of lacosamide accounts for 70% to 95% of total lacosamide (ER+IR)
This tightens the Claim 1 ratio range.
What materials are explicitly included?
Extended release agents list (Claim 15)
Claim 15 enumerates ER agent selection:
- ethyl cellulose
- methyl cellulose
- cellulose acetate
- polyvinyl acetate
- ethyl acrylate/methyl methacrylate/trimethylamino ethyl methacrylate chloride copolymer
- ethyl acrylate/methyl methacrylate/trimethylamino ethyl methacrylate chloride copolymer (second entry repeats polymer listing)
- hydroxypropyl methylcellulose
- sodium carboxymethyl cellulose
- povidone
- polyethylene
Practically, this creates claim support for common hydrophobic and hydrophilic ER systems and polymeric matrix/coating approaches. It does not foreclose other ER agents unless dependent-claim narrowing is used to attack validity or infringement.
What in-vitro dissolution performance is required?
Claim 16 sets a three-point dissolution profile using USP apparatus conditions:
- System: USP Type 1 (basket)
- 100 rpm
- 37 ± 0.5°C
- 900 mL pH 6.8 phosphate buffer
- Timepoints:
- < 20% in 1 hour
- 20% to 80% in 4 hours
- > 80% in 12 hours
Claim 17 provides tighter multi-point ranges:
- 11% to 18% in 1 hour
- 20% to 35% in 2 hours
- 40% to 70% in 4 hours
- 65% to 95% in 6 hours
- > 90% in 12 hours
From an enforcement standpoint, these dissolution constraints are meaningful because they link formulation mechanics to later exposure, reinforcing the AUC-driven novelty.
What method claims expand coverage beyond product?
Claim 18: generating a target AUC profile
This claim covers the act of administering the dosage form to generate a desired exposure pattern.
- It repeats the Claim 1 target AUC conditions:
- AUC0-3h ≥ 40% of reference
- AUC0-6h ≥ 60% of reference
- AUC12-24h 80% to 125% of reference
Claims 19-21: therapeutic use breadth
- Claim 19: subject has a neurological or psychiatric disease/condition.
- Claim 20: method of treating neurological or psychiatric disease/condition via administering the dosage form.
- Claim 21: enumerates an extensive disease list including:
- epilepsy
- migraine
- essential tremor
- restless limb syndrome
- cluster headache
- neuralgia
- neuropathic pain
- and multiple psychiatric conditions such as anxiety, bipolar disorder, psychosis, mania, schizophrenia, depression, dementia, and others
- includes ALS and several neurodevelopmental and impulse-control disorders
This makes the patent a multi-therapy platform at the claim level, with the dosage form being the key enabling element.
Scope map: what is in and out of infringement risk
In-scope product features (high confidence from claim text)
A product most exposed to infringement is one that has:
- lacosamide (or salt)
- once-daily oral dosing
- ER + IR split
- ER/IR drug ratio within:
- total drug loading ≥ 20% by weight
- AUC0-3h, AUC0-6h minimums and AUC12-24h range meet Claim 1 thresholds
- optional dependent narrowing points (if asserted) like:
- ER drug fraction 70% to 95%
- dissolution profile within Claims 16-17 bands
- specific architecture like IR layer enclosing ER matrix or two-layer compressed tablet
- selection of listed ER agents
Key “design-around” pressure points
The claims create three technical pressure points that are typically hard to circumvent without changing performance targets:
- AUC target matching to a reference IR twice-daily regimen
- Drug split ratio by weight (15:1 to 1:1)
- Dissolution constraints at defined pH 6.8 and basket apparatus conditions (Claims 16-17)
Products can still avoid infringement by failing at least one of the required performance metrics, assuming the relevant dependent claims are not asserted and the product remains outside Claim 1’s AUC gating.
What does the patent landscape likely look like around this claim family?
With lacosamide, the landscape typically clusters into:
- Immediate-release generics and alternative salts
- Extended-release reformulations (often using matrix/coating, multi-particulate systems, or layered tablets)
- PK-optimized ER once-daily “AUC matching” strategies versus IR twice daily
- Device and processing-related patents tied to multi-particulates, coatings, and compression methods
- Oral dosage form patents across multiple epilepsy and pain indications
Within that landscape, the distinctive stance of US 12,042,474 is its explicit AUC-window framing against a defined IR comparator and its explicit ER/IR ratio requirements. That shifts the patent from “generic ER formulation” toward “PK-controlled release engineered to match IR exposure.”
How to read this patent for freedom-to-operate (FTO) screening
Claim triage matrix
Treat infringement screening as a sequence:
- Is the product once-daily and oral?
- Does it contain both IR and ER lacosamide fractions?
- Is total lacosamide loading ≥ 20% by weight?
- Is the ER:IR lacosamide ratio within 15:1 to 1:1?
- Does the PK profile meet Claim 1 AUC gating versus a matched IR twice-daily reference?
- If yes, assess whether dependent claim conditions (dissolution bands, ER fraction 70%-95%, layered/enclosed architecture, specific ER polymers) are also met.
If a candidate product fails any earlier gate, it falls out quickly. If it passes all, the product likely requires more detailed claim-by-claim performance mapping.
Key Takeaways
- US 12,042,474 protects a once-daily oral lacosamide IR+ER dosage form defined by drug ratio (15:1 to 1:1), minimum total loading (≥20% by weight), and quantitative AUC targets against a twice-daily IR reference.
- Claim 1 is performance-anchored through AUC0-3h, AUC0-6h minimums and AUC12-24h 80% to 125%.
- Dependent claims expand the exposure envelope across additional time windows and can narrow further via ER drug fraction (70% to 95%), USP dissolution profiles, and specific ER agent selections.
- Method claims convert product use into exposure-generation and broad therapeutic treatment claims, with an extensive neurological and psychiatric disease list.
FAQs
1) Is the AUC target the primary differentiator of this patent?
Yes. Claim 1’s scope hinges on meeting specified AUC windows versus a defined twice-daily IR reference. Formulation architecture becomes secondary to that exposure gate.
2) Does the patent require any specific ER agent chemistry?
Claim 15 lists specific extended release agents, but other ER agents are not automatically excluded at the independent-claim level. Dependent-claim assertions would depend on the specific product formulation.
3) What dissolution method and conditions are explicitly defined?
Claim 16 and 17 specify USP Type 1 basket at 100 rpm, 37 ± 0.5°C, 900 mL pH 6.8 phosphate buffer, with defined dissolution percentages at multiple timepoints.
4) Can the IR and ER portions be physically separate?
Yes. Claims 9 and 10 cover admixed versus physically separate ER and IR particulates, including configurations where each portion is in its own particulates.
5) Are the therapeutic indications limited to epilepsy?
No. Claim 21 includes a broad list spanning epilepsy and multiple neurological and psychiatric conditions.
References
- United States Patent No. 12,042,474 (claims as provided in prompt).
